Hayward, California-based Chrono Therapeutics, which is developing a sensor-enabled nicotine patch with a connected app, has raised $47.6 million in Series B financing. The round was led by Kaiser Permanente Ventures and will go towards further development of the company’s digital drug therapy platform.
Chrono Therapeutics’ flagship product, which won’t be ready for consumers until as late as...
